EGFR and neoplasm: Thus, a tumor of squamous origin with biomarkers/profile indicating dependence on EGFR signaling might be prevented from metastasizing by combining therapies that target EGFR signaling and iCa2+ signaling, while the combination might be counterproductive in another context.